Efficacy And SafetyIn dose escalation Phase 1b, the '944 combination data showed favorable efficacy and safety compared to Pfizer's mevrometostat.
Financial PositionORIC announced a concurrent private placement raising $125 million, extending cash runway into the second half of 2027 and through the anticipated primary endpoint readout from the planned Phase 3 trial in mCRPC.
Prostate Cancer TreatmentSolid prostate cancer data with two separate AR inhibitors, along with a clean safety profile, well positions ORIC's drug in the metastatic castration-resistant prostate cancer market.